Updated on 15 August 2012
Singapore: Biostar Pharmaceuticals, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, released its financial results for the second quarter and six months ended June 30, 2012, which were severely affected by the temporary PRC government imposed suspension of gel capsule sales.
Net sales for Q2 this year decreased to $8.2 million from $25.9 million and
Gross margin also decreased to 56 percent as compared to 71.9 percent last year in Q2 2011.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
